TNFRSF8 and Hodgkins lymphoma: BER-H2-SO6 IT, as described in previous in vitro and in vivo preclinical studies, shows selective and potent cytotoxicity for CD30+ cell lines [42,43], making this a good candidate therapeutic molecule for the treatment of Hodgkin’s disease (HD) and CD30+ large cell lymphomas [44,45].